Abstract
Distribution of valuable research discoveries are needed for the continual advancement of patient care. Publication and subsequent reliance of false study results would be detrimental for patient care. Unfortunately, research misconduct may originate from many sources. While there is evidence of ongoing research misconduct in all it's forms, it is challenging to identify the actual occurrence of research misconduct, which is especially true for misconduct in clinical trials. Research misconduct is challenging to measure and there are few studies reporting the prevalence or underlying causes of research misconduct among biomedical researchers. Reported prevalence estimates of misconduct are probably underestimates, and range from 0.3% to 4.9%. There have been efforts to measure the prevalence of research misconduct; however, the relatively few published studies are not freely comparable because of varying characterizations of research misconduct and the methods used for data collection. There are some signs which may point to an increased possibility of research misconduct, however there is a need for continued self-policing by biomedical researchers. There are existing resources to assist in ensuring appropriate statistical methods and preventing other types of research fraud. These included the "Statistical Analyses and Methods in the Published Literature", also known as the SAMPL guidelines, which help scientists determine the appropriate method of reporting various statistical methods; the "Strengthening Analytical Thinking for Observational Studies", or the STRATOS, which emphases on execution and interpretation of results; and the Committee on Publication Ethics (COPE), which was created in 1997 to deliver guidance about publication ethics. COPE has a sequence of views and strategies grounded in the values of honesty and accuracy.
Collapse